

Harrys A Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7570935/publications.pdf>

Version: 2024-02-01

62
papers

1,664
citations

394421

19
h-index

289244

40
g-index

62
all docs

62
docs citations

62
times ranked

2152
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B virus and hepatitis C virus reactivation in cancer patients receiving novel anticancer therapies. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1321-1327.	6.0	14
2	Strategies to identify hepatitis C virus infection in patients receiving anticancer therapy: a cross-sectional study. <i>Supportive Care in Cancer</i> , 2021, 29, 97-105.	2.2	0
3	Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 844-848.	2.0	0
4	Nursing practice is associated with high risk for hepatitis C virus infection. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1362-1364.	6.0	1
5	Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e124-e127.	0.4	11
6	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466.	7.2	30
7	Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus-infected patients. <i>Hematological Oncology</i> , 2020, 38, 301-308.	1.7	6
8	Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. <i>Seminars in Oncology</i> , 2020, 47, 165-167.	2.2	0
9	False-positive <i>Trypanosoma cruzi</i> serology in a cancer patient receiving intravenous immunoglobulin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115057.	1.8	2
10	Salvage therapy in cancer patients with hepatitis C without sustained virologic response after direct-acting antivirals: A prospective study. <i>JGH Open</i> , 2020, 4, 541-544.	1.6	1
11	Virologic Impact of Radiotherapy in Hepatitis C Virus-Infected Patients With Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 775-777.	7.3	4
12	Hepatitis C Virus Infection in Patients With Cancer: Impact on Clinical Trial Enrollment, Selection of Therapy, and Prognosis. <i>Gastroenterology</i> , 2019, 157, 909-916.	1.3	23
13	Oncologic Implications of Chronic Hepatitis C Virus Infection. <i>Journal of Oncology Practice</i> , 2019, 15, 629-637.	2.5	19
14	Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 250-257.	0.4	17
15	The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection. <i>Gut</i> , 2018, 67, 553-561.	12.1	101
16	Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. <i>Hepatology</i> , 2018, 67, 36-47.	7.3	96
17	Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. <i>International Journal of Cancer</i> , 2018, 142, 940-948.	5.1	13
18	Impact of chronic hepatitis C virus infection on the survival of patients with oropharyngeal cancer. <i>Cancer</i> , 2018, 124, 960-965.	4.1	10

#	ARTICLE	IF	CITATIONS
19	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 959-967.	1.6	18
20	2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S658-S659.	0.9	0
21	2228. Late Viral Relapse After Direct-Acting Antiviral Treatment in Hepatitis C Virus-Infected Cancer Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S659-S659.	0.9	0
22	Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 262-279.	3.8	160
23	Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. <i>Current Opinion in Infectious Diseases</i> , 2018, 31, 535-541.	3.1	7
24	2226. Immune Checkpoint Inhibitors in Solid Tumor Patients with Chronic Hepatitis C Virus Infection: A Prospective Case-Series. <i>Open Forum Infectious Diseases</i> , 2018, 5, S658-S658.	0.9	4
25	Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. <i>Lancet Haematology</i> , 2018, 5, e474-e478.	4.6	20
26	Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. <i>World Journal of Hepatology</i> , 2018, 10, 549-557.	2.0	9
27	Inhibition of Hepatitis C Virus Replication Induced by Chemotherapy: A Prospective Observational Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1635-1636.	5.8	4
28	Chronic hepatitis C virus infection in patients with nonoropharyngeal head and neck cancers. <i>Oral Oncology</i> , 2018, 85, 103-105.	1.5	2
29	Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer. <i>Journal of Hepatocellular Carcinoma</i> , 2018, Volume 5, 81-86.	3.7	6
30	Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different primary malignancy. <i>Leukemia and Lymphoma</i> , 2017, 58, 485-488.	1.3	7
31	Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study. <i>Cancer</i> , 2017, 123, 1202-1211.	4.1	79
32	The oncologic burden of hepatitis C virus infection: A clinical perspective. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 411-431.	329.8	88
33	Sofosbuvir-based therapy in patients with chronic hepatitis C virus infection and malignancies: A prospective study of 143 patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18152-e18152.	1.6	4
34	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	1.4	149
35	Association Between Hepatitis C Virus and Head and Neck Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw035.	6.3	57
36	Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. <i>International Journal of Cancer</i> , 2016, 139, 2519-2528.	5.1	32

#	ARTICLE	IF	CITATIONS
37	How I treat hepatitis C virus infection in patients with hematologic malignancies. <i>Blood</i> , 2016, 128, 1449-1457.	1.4	27
38	Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1185-1188.	4.9	2
39	Prevalence and association of hepatitis <sc>C</sc> virus infection with different types of lymphoma. <i>International Journal of Cancer</i> , 2016, 138, 1035-1037.	5.1	24
40	Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. <i>Journal of Hepatology</i> , 2016, 65, 862-864.	3.7	73
41	Management of Multiple Myeloma Complicated by Hepatitis C Virus Reactivation: The Role of New Antiviral Therapy. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofv211.	0.9	8
42	The effect of different rituximab-containing chemotherapy strategies on hepatitis C viremia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1487-1490.	1.3	0
43	Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 717-722.	2.0	49
44	Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 41-50.	4.9	22
45	Hepatocellular carcinoma as a second primary cancer in patients with chronic hepatitis C virus infection. <i>Digestive and Liver Disease</i> , 2015, 47, 348-349.	0.9	4
46	Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization. <i>Liver International</i> , 2015, 35, 1661-1664.	3.9	19
47	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1870-1882.	2.0	54
48	HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. <i>Journal of Oncology Practice</i> , 2015, 11, 384-390.	2.5	17
49	Impact of hepatitis <sc>E</sc> virus seropositivity on chronic liver disease in cancer patients with hepatitis <sc>C</sc> virus infection. <i>Hepatology Research</i> , 2015, 45, 1146-1151.	3.4	10
50	Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. <i>Journal of Clinical Oncology</i> , 2015, 33, 7090-7090.	1.6	2
51	Sustained Virologic Response After 6 Weeks of Therapy With a First-Generation Hepatitis C Virus Protease Inhibitor. <i>Clinical Infectious Diseases</i> , 2014, 58, 1342-1344.	5.8	1
52	Does Chemotherapy Cause Viral Relapse in Cancer Patients With Hepatitis C Infection Successfully Treated With Antivirals?. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1051-1054.e1.	4.4	19
53	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. <i>Journal of Oncology Practice</i> , 2014, 10, e167-e174.	2.5	19
54	Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis C Virus Infection: A Case Series. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 451-456.	6.7	3

#	ARTICLE	IF	CITATIONS
55	Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients. <i>Blood</i> , 2014, 124, 4126-4126.	1.4	1
56	Challenges in managing hepatitis C virus infection in cancer patients. <i>World Journal of Gastroenterology</i> , 2014, 20, 2771.	3.3	31
57	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2013, 5, 332.	2.0	2
58	Hepatitis C Clinic Operated by Infectious Disease Specialists at a Comprehensive Cancer Center: Help Is on the Way. <i>Clinical Infectious Diseases</i> , 2012, 54, 740-742.	5.8	9
59	The Effect of Transcatheter Arterial Chemoembolization on Hepatitis C Viremia. <i>Oncologist</i> , 2012, 17, e21-e23.	3.7	3
60	Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. <i>Journal of Hepatology</i> , 2012, 57, 1177-1185.	3.7	112
61	Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study. <i>Journal of Clinical Virology</i> , 2012, 54, 218-222.	3.1	11
62	Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 156-166.	27.6	148